Nanox Imaging Announcement: Secures over $100M in Crossover Equity Investments

Nanox Imaging (Nanox) today reports they have secured over $100M in crossover equity investments. The news was announced today. Israeli-based A-Labs Advisory and Finance Ltd. was the lead advisor to the financing round.

The funds raised are planned to primarily support the rollout of the Nanox.ARC deployments worldwide.

The financing round was initiated in November 2019 and was delayed in closing due to the COVID-19 pandemic. Since November 2019, Nanox has signed agreements for the deployment of thousands of units of the Nanox System, its innovative medical imaging system, and diagnostics services in eleven global regions. The Company aims to revolutionize early-detection healthcare by deploying a global medical imaging infrastructure at an affordable price-per-scan service model to maximize the availability and accessibility of medical imaging to all socio-economic communities.

“It is easy to say that we are aiming to change the world,” says Ran Poliakine, Founder and Chief Executive Officer of Nanox. “The main challenge with such statements is always the execution. We have a bold vision to increase the early detection of medical conditions that are discoverable by X-ray. We are actively working to deploy a global medical imaging service infrastructure that may turn this dream into reality. We cannot do it without partners and investors who share our vision and support our plan. I thank our investors at SK Telecom, Foxconn, Industrial Alliance and Yozma Korea for their faith and trust in the Nanox team and vision.”

“The innovative approach of preventive healthcare and the MEMs X-ray source have driven us, The Yozma Group Asia, to invest in Nanox. Potentially reduced radiation exposure and lowered cost can set a new standard of regular health checkups,” says Wonjae Lee, Head of Asia Pacific and Managing Partner of Yozma Group. “I’m honored to be a part of the Nanox project not only because its technology is groundbreaking and contributing to mankind, but also because it’s the best example of multinational collaboration. As a strategic investor, The Yozma Group Asia is eager to make a global success case of Asian and Israeli collaboration by merging Nanox innovative technology and Korea’s outstanding manufacturing knowhow.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version